ClinicalTrials.gg
CompletedNCT03555422ENGOT-EN5Updated Apr 13, 2026

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

A Phase 3 interventional study of Selinexor and Matching placebo for selinexor in Endometrial Cancer, sponsored by Karyopharm Therapeutics Inc. Completed at 78 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Karyopharm Therapeutics Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 9 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Jan 2018, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 287 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
107th of 591
263 · median 60
Started
2018
with 32 others
Phase 3
39 of 715
12 open now
Registered
326th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 107th largest by enrollment of the 591 interventional ones that give a count, is one of 33 that started in 2018, is one of 39 in phase 3, and was the 326th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 471 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 357 Endometrial Neoplasms studies recruiting now, 267 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial Neoplasms
  • Uterine Neoplasms
  • Genital Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Uterine Diseases
  • Genital Diseases
  • Female
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, at least 18 years of age at the time of .
  • Histological confirmed endometrial cancer of the endometrioid, serous, or undifferentiated type. Carcinosarcoma of the uterus is also allowed.
  • Completed a single line of at least 12 weeks of taxane-platinum combination therapy (not including or neoadjuvant therapy), and achieved partial remission (PR) or complete remission (CR) according to version 1.1 for:
  • Primary Stage IV disease, defined as:
  • had a primary or later debulking surgery during taxane-platinum therapy with R0 resection (R0 resection indicates a macroscopic complete resection of all visible tumor) and achieved CR after at least 12 weeks taxane-platinum chemotherapy, OR
  • had a primary or later debulking surgery during first-line taxane-platinum therapy with R1 resection (R1 resection indicates incomplete removal of all macroscopic disease,) and achieved PR or CR after at least 12 weeks taxane-platinum chemotherapy, OR
  • had no surgery and achieved PR or CR after at least 12 weeks taxane-platinum chemotherapy.

OR

  • At first relapse (i.e., relapse after primary therapy including surgery and/or chemotherapy therapy for Stage I-IV disease), defined as:
  • had Stage I-III disease at diagnosis and received at initial diagnosis adjuvant chemotherapy and later. Participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse, OR
  • had Stage I-III disease at diagnosis and did not receive adjuvant chemotherapy at initial diagnosis and relapsed later. Participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse, OR
  • had Stage IV disease at diagnosis and received initially chemotherapy with or without surgery and relapsed later. At the time of relapse, participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse.

Participants that required their chemotherapy dose held during the 12-week therapy may be considered if they meet the other criteria above and achieve PR or CR per RECIST V1.1.

  • Must be able to initiate study drug 5 to 8 weeks after completion of their final dose of chemotherapy.
  • (ECOG) performance status of 0-1.
  • Participants must have adequate bone marrow function and organ function within 2 weeks before starting study drug as defined by the following laboratory criteria:
  • Hepatic function: total up to 1.5* (ULN); (ALT) and aspartate aminotransferase (AST) less than or equal to (≤) 2.5*ULN in participants without liver . For participants with known liver involvement of their tumor: AST and ALT ≤5*ULN.
  • Hematopoetic function: (ANC) greater than or equal to (≥) 1.5*10\^9/L; count ≥100*10\^9 per liter (/L); ≥9.0 gram per deciliter (g/dL).
  • Renal function: estimated (CrCl) of ≥20 milliliter per minute (mL/min), calculated using the Cockroft Gault formula.
  • In the opinion of the Investigator, the participant must:
  • Have a of at least 12 weeks, and
  • Be fit to receive experimental therapy.
  • Premenopausal females of must have a negative pregnancy test (serum β-human chorionic gonadotropin test) prior to the first dose of study drug. Female participants of childbearing potential must agree to use highly effective methods of throughout the study and for 1 week following the last dose of study drug.
  • Written informed consent in accordance with federal, local, and institutional guidelines. The participant must provide informed consent prior to the first Screening procedure.

Exclusion criteria

Exclusion Criteria:

  • Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas.
  • Received a blood or transfusion during 4 weeks prior to randomization.
  • Being treated with a concurrent cancer therapy.
  • Previous treatment with an exportin 1 (XPO1) inhibitor.
  • Previous treatment with anti- programmed cell death protein 1 () or anti-programmed cell death ligand-1 (PD-L1) immunotherapy (e.g., pembrolizumab).
  • Concurrent treatment with an agent or participation in another clinical trial.
  • Participants who received any systemic anticancer therapy including investigational agents or radiation ≤3 weeks (or ≤5 half-lives of the drug [whichever is shorter]) prior to cycle 1 day 1 (C1D1). Palliative radiotherapy may be permitted for symptomatic control of pain from bone in extremities, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect progressive disease (PD).
  • Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during the on-treatment study period.
  • Previous malignant disease, except participants with other malignant disease, for which the participant has been disease-free for at least 3 years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
  • Any life-threatening illness, medical condition or organ system dysfunction, which, in the investigator's opinion, could compromise the participant's safety or compliance with the protocol.
  • Known to selinexor.
  • Known uncontrolled to the investigational drug, or to its .
  • Radiotherapy to the target lesion within the past 3 months prior to baseline imaging.
  • Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with the exception of alopecia.
  • Active (e.g., stable for \<8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization).
  • Known unstable cardiovascular function:
  • Symptomatic ischemia, or
  • Uncontrolled conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block /right bundle branch block will not be excluded), or
  • Congestive heart failure of Class ≥3, or
  • Myocardial infarction within 3 months
  • Females who are pregnant or actively breastfeeding.
  • Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
  • Active and/or B infection.
  • Participants unable to swallow tablets, participants with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study drug. A history of bowel obstruction requiring a nasogastric tube or intravenous infusion during the past 2 months is not allowed (except when this obstruction is caused by surgery or other non-malignant causes).
  • Psychiatric illness or substance use that would prevent the participant from giving or being compliant with the study procedures.
  • Participants unwilling or unable to comply with the protocol.
  • Persons who have been committed to an institution by official or judicial order.
  • Participants with dependency on the Sponsor, Investigator or study site.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    Selinexor

    Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index \[BMI\] less than \[\<\] 20 kilogram per meter square \[kg/m\^2\]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: Selinexor

  • Placebo comparator
    Matching placebo for selinexor

    Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: Matching placebo for selinexor

Interventions

  • Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

  • DrugMatching placebo for selinexor

    Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Compare progression free survival of the two treatment arms as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled)

Secondary outcomes

  1. Progression Free Survival: Assessed by Blinded Independent Central Review (BICR), per RECIST v1.1

    Time from randomization until documented PD or death due to any cause, whichever occurs first. Documented PD will be based on BICR assessments.

    Time frame: Time from randomization until PD or death, whichever occurs first (approximately 12 months after the last participant enrolled)

  2. Disease Specific Survival (DSS)

    Time from randomization until date of death from endometrial cancer.

    Time frame: Time from randomization until death from endometrial cancer (approximately 12 months after the last participant enrolled)

  3. Overall Survival (OS)

    Time from randomization until date of death from any cause.

    Time frame: Time from randomization until death (approximately 12 months after the last participant enrolled)

  4. Time to First Subsequent Treatment (TFST)

    Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first.

    Time frame: Time from randomization until first therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)

  5. Progression-free Survival After Subsequent Treatment (PFS2)

    Time from randomization until the second documented disease progression or death due to any cause by any cause on any subsequent line of anticancer therapy.

    Time frame: Time from randomization until second documented PD or death (approximately 12 months after the last participant enrolled)

  6. Time to Second Subsequent Treatment (TSST)

    Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first.

    Time frame: Time from randomization until second therapy initiation after discontinuation of study drug or death, whichever occurs first (approximately 12 months after the last participant enrolled)

  7. Disease Control Rate (DCR)

    Best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) among patients with PR as best response to prior chemotherapy.

    Time frame: Time from randomization up to approximately 16 weeks

  8. Health-Related Quality of Life (HR-QoL): Measured by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30

    Patient-reported outcomes will be measured by the EORTC QLQ C30 questionnaire.

    Time frame: Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)

  9. Health-Related Quality of Life: Measured by EORTC QLQ-EN24

    Patient-reported outcomes will be measured by the EORTC QLQ-EN24 questionnaire.

    Time frame: Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)

  10. Health-Related Quality of Life: Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)

    Patient-reported outcomes will be measured by the EORTC EQ-5D-5L.

    Time frame: Every 12 weeks during study period, at PD and post PD at 3 and 6 months (approximately 12 months after the last participant enrolled)

  11. Number of Participants with Treatment Emergent Adverse Events (TEAEs), Occurrence, Nature, and Severity of AEs

    Time frame: From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)

  12. Number of Participants with Significant Physical Examination, Clinical Laboratory, and Vital Signs Results

    Time frame: From first drug administration up to 30 days after last dose (approximately 12 months after the last patient enrolled)

07

Study locations

78 sites
  • Arizona Oncology
    Tucson, Arizona 85711, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Florida Cancer Specialists (Sarah Cannon Research Institute)
    West Palm Beach, Florida 33401, United States
  • Gynecological Cancer Institute of Chicago
    Oak Lawn, Illinois 60453, United States
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
  • Indiana University Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • HCA Midwest Health - Kansas City (Sarah Cannon Research Institute)
    Kansas City, Missouri 64132, United States
  • NYU Langone
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of Oklahoma Health Sciences Center - Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Oncology Associates of Oregon
    Eugene, Oregon 97401, United States
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
  • Tennessee Oncology Nashville (Sarah Cannon Research Institute)
    Nashville, Tennessee 37203, United States
  • Texas Oncology, Austin
    Austin, Texas 78731, United States
  • Texas Oncology DFW
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Oncology DFW
    Fort Worth, Texas 76104, United States
  • VCU Massey Cancer Center
    Richmond, Virginia 23298, United States
  • UZ Gent
    Ghent, 9000, Belgium
  • Jan Yperman Ziekenhuis
    Ieper, 8900, Belgium
  • Universitaire Ziekenhuizen K.U. Leuven
    Leuven, 3000, Belgium
  • CHU UCL Namur, Site Sainte-Elisabeth
    Namur, 5000, Belgium
  • AZ Turnhout
    Turnhout, 2300, Belgium
  • CHR Verviers
    Verviers, 4800, Belgium
  • London Health Sciences Centre (London Regional Cancer Centre)
    London, Ontario N6C 0A7, Canada
  • University Health Network (PMCC)
    Toronto, Ontario M5G 2M9, Canada
  • McGill University Health Centre (MUHC)
    Montreal, Quebec H4A 3J1, Canada
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150040, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi 330006, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
  • Chongqing University Cancer Hospital
    Chongqing, Shapingba District 400000, China
  • Wenzhou Medical University - The First Affiliated Hospital
    Wenzhou, Zhejiang 325000, China
  • University Hospital Brno
    Brno, 60200, Czechia
  • University Hospital Ostrava
    Ostrava, 70852, Czechia
  • UH Královské Vinohrady
    Prague, 10034, Czechia
  • General University Hospital in Prague
    Prague, 12851, Czechia
  • Hospital Na Bulovce
    Prague, 18081, Czechia
  • Charite Berlin Universitatsmedizin
    Berlin, 13353, Germany
  • University Hospital Dresden
    Dresden, 01307, Germany
  • DIAKOVERE KH gGmbH, Henriettenstift Hannover
    Hanover, 30171, Germany
  • Universitatsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Universitätsfrauenklinik Mainz
    Mainz, 55131, Germany
  • Klinikum der Universitat Munchen
    Munich, 80337, Germany
  • Cartitas Klinikum Saarbrücken
    Saarbrücken, 66113, Germany
  • Universitätsfrauenklinik Ulm
    Ulm, 89070, Germany
  • Iaso Hospital
    Marousi, Athens 151 23, Greece
  • ALEXANDRA Hospital
    Athens, Greece 11528, Greece
  • Euromedica General Clinic
    Thessaloniki, Macedonia 54645, Greece
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Wolfson Medical Center
    Holon, 58100, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Hadassah Medical Center
    Jerusalem, 9112001, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Istituto di Candiolo, FPO, IRCCS
    Candiolo, 10060, Italy
  • Romagnolo Scientific Institute for the Study and Treatment of Tumors
    Meldola, 47014, Italy
  • San Raffaele Hospital
    Milan, 20132, Italy
  • Istituto Nazionale dei Tumori IRCCS - MILANO S.C. Ginecologia Oncologica
    Milan, 20133, Italy
  • ULSS 3 SERENISSIMA UOC Oncologia Ed Ematologia Oncologica
    Mirano, 30174, Italy
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" - NAPOLI Struttura Complessa Oncologia Medica Uro-Ginecologica
    Naples, 80131, Italy
  • Agostino Gemelli University Polyclinic Foundation
    Rome, 30161, Italy
  • Hospital Universitario Donostia
    San Sebastián, Gipuzkoa 20014, Spain
  • Hospital Universitari Vall d' Hebrón
    Barcelona, 08035, Spain
  • Hospital Universitari Clínic de Barcelona
    Barcelona, 08036, Spain
  • Consorci Sanitari de Terrassa
    Barcelona, 08227, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda
    Madrid, 28220, Spain
  • Hospital Universitario Infanta Sofía
    Madrid, 28702, Spain
  • Virgen de la Arrixaca University Clinical Hospital
    Murcia, 30120, Spain
  • Hospital Son Llàtzer
    Palma, 071998, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
  • Instituto Valenciano de Oncología
    Valencia, 46009, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Universitario y Politécnico de La Fe
    Valencia, 46026, Spain
  • Hospital Clínico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
08

References and documents

Publications

  • Vergote I, Perez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martinez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Hogdall E, Farinas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. PubMed 37669480 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Jan 2022, 48 months.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 48 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2018
First posted
Jun 13, 2018
StartActual
Jan 5, 2018
Primary completionActual
Jan 22, 2022
CompletionActual
Apr 3, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03555422
Collaborators
Belgian Gynaecological Oncology Group, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, GOG Foundation, Multicenter Italian Trials in Ovarian Cancer (MITO), Grupo Español de Investigación en Cáncer de Ovario, North Eastern German Society of Gynaecological Oncology
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Jan 5, 2018
Primary completion
Jan 22, 2022
Completion
Apr 3, 2025
Last update
Apr 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion